人类卡利克莱因2:在前列腺癌中,一种新的血统特定的表面标
Fei Shen1, Ryan Smith2, Theresa McDevitt2
1Johnson and Johnson, Spring House, United States.
概括
人类kallikrein 2 (KLK2) 是一种前列腺特异性抗原,现在已被证实是前列腺癌 (PCa) 的细胞表面标. 用新疗法向KLK2显示出在先进的PCa中显著的临床前疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 转移性前列腺癌 (PCa) 缺乏有效的向疗法,需要新的药物向和作用机制 (MoA).
- 人类kallikrein 2 (KLK2),一个前列腺特异性抗原,由于对其表达的先前假设,作为治疗点尚未被充分探索.
- 细胞表面表达的有限证据在历史上阻碍了KLK2在PCa中被视为可行的标.
研究的目的:
- 系统地描述整个PCa疾病连续的KLK2表达.
- 为了确认前列腺癌中KLK2的细胞表面表达.
- 评估 KLK2 向治疗药物的临床前疗效,具有明显的 MOA.
主要方法:
- 免疫组织化学和多重免疫光染色以评估KLK2表达特征.
- 使用PCa细胞系和来自患者的材料进行体外研究.
- 在体内异种移植的小鼠模型来评估治疗疗效.
主要成果:
- KLK2在局部和荷尔蒙敏感的PCa中表达强大和均,在转移性割耐药PCa中有一定的异质性.
- 与其他PCa抗原相比,KLK2的特异性更高,并且已证实在细胞表面表达.
- 三种不同的KLK2向治疗药物 (双特异性T细胞重定向剂,向性α-放射性,CAR T) 显示出强烈的体外活性和显著的体内瘤控制.
结论:
- KLK2被验证为PCa.的高度前列腺特异性细胞表面标.
- 准KLK2为晚期前列腺癌提供了有前途的新型治疗策略.
- 评估的多种MoA为开发有效的基于KLK2的疗法提供了多种途径.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K